Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal management of Marfan syndrome
NL-OMON51432Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of metoprolol and losartan in Marfan syndrome (MFS), sponsored by Amsterdam University Medical Center. Primary endpoints: Advanced MRI differences between Marfan syndrome and healthy controls, Advanced MRI changes before and after PEARS and 1 more. Planned start Sep 2022; status: withdrawn.
02
Drugs
metoprolollosartan
03
Conditions
Marfan syndrome (MFS)
Beyond the preview
Go deeper on NL-OMON51432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51432.